Polycystic ovary syndrome: chemical pharmacotherapy

Bibliography

• Adams J, Polson DW, Franks S. Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism. Br Med J (Clin Res Ed) 1986;293:355-9
   PubMed Web of Science ®Google Scholar
• Balen A. Pathogenesis of polycystic ovary syndrome--the enigma unravels? Lancet 1999;354:966-7
   PubMed Web of Science ®Google Scholar
• Michelmore KF, Balen AH, Dunger DB, Vessey MP. Polycystic ovaries and associated clinical and biochemical features in young women. Clin Endocrinol (Oxf) 1999;51:779-86
   PubMed Web of Science ®Google Scholar
• Legro RS. Polycystic ovary syndrome: current and future treatment paradigms. Am J Obstet Gynecol 1998;179(Suppl):101-8
   Google Scholar
• Tsilchorozidou T, Overton C, Conway GS. The pathophysiology of polycystic ovary syndrome. Clin Endocrinol (Oxf) 2004;60:1-17
   PubMed Web of Science ®Google Scholar
• Balen AH. Is metformin the treatment of choice for anovulation in polycystic ovary syndrome? Nat Clin Pract Endocrinol Metab 2007;3:440-1
   PubMedGoogle Scholar
• Stein FI, Leventhal LM. Amenorrhoea associated with bilateral polycystic ovaries. Am J Obstet Gynecol 1935;29:181-5
   Google Scholar
• Dunaif A, Chang RJ, Franks S, Legro RS. Polycystic ovary syndrome. current controversis, from the ovary to the pancreas. Humana Press; 2008
   Google Scholar
• Rotterdam ESRHE/ASRM 2003-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19:41-7
   PubMedGoogle Scholar
• Azziz R, Carmina E, Dewailly D, et al. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab 2006;91:4237-45
   PubMed Web of Science ®Google Scholar
• Legro RS, Arslanian SA, Ehrmann DA, et al. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2013;98:4565-92
   PubMed Web of Science ®Google Scholar
• Moran LJ, Hutchison SK, Norman RJ, Teede HJ. Lifestyle changes in women with polycystic ovary syndrome. Cochrane Database Syst Rev 2011;7:CD007506
   PubMedGoogle Scholar
• Chang WY, Knochenhauer ES, Bartolucci AA, Azziz R. Phenotypic spectrum of polycystic ovary syndrome: clinical and biochemical characterization of the three major clinical subgroups. Fertil Steril 2005;83:1717-23
   PubMed Web of Science ®Google Scholar
• Azziz R, Sanchez LA, Knochenhauer ES, et al. Androgen excess in women: experience with over 1000 consecutive patients. J Clin Endocrinol Metab 2004;89:453-62
   PubMed Web of Science ®Google Scholar
• Azziz R, Woods KS, Reyna R, et al. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004;89:2745-9
   PubMed Web of Science ®Google Scholar
• Azziz R, Carmina E, Dewailly D, et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril 2009;91:456-88
   PubMed Web of Science ®Google Scholar
• Quinn M, Shinkai K, Pasch L, et al. Prevalence of androgenic alopecia in patients with polycystic ovary syndrome and characterization of associated clinical and biochemical features. Fertil Steril 2014;101:1129-34
   PubMedGoogle Scholar
• Escobar-Morreale HF, Carmina E, Dewailly D, et al. Epidemiology, diagnosis and management of hirsutism: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome Society. Hum Reprod Update 2012;18:146-70
   PubMed Web of Science ®Google Scholar
• Wolf Jr JE, Shander D, Huber F, et al. Randomized, double-blind clinical evaluation of the efficacy and safety of topical eflornithine HCl 13.9% cream in the treatment of women with facial hair. Int J Dermatol 2007;46:94-8
   PubMedGoogle Scholar
• ACOG Committee on Practice Bulletins Gynecology. ACOG Practice Bulletin No. 108: Polycystic ovary syndrome. Obstet Gynecol 2009;114:936-49
   PubMedGoogle Scholar
• Pasquali R, Gambineri A. Therapy in endocrine disease: treatment of hirsutism in the polycystic ovary syndrome. Eur J Endocrinol 2013;170:R75-90
   PubMed Web of Science ®Google Scholar
• Vrbìkovà J, Cibula D. Combined oral contraceptives in the treatment of polycystic ovary syndrome. Hum Reprod Update 2005;11:277-91
   PubMed Web of Science ®Google Scholar
• De Leo V, Morgante G, Piomboni P, et al. Evaluation of effects of an oral contraceptive containing ethinylestradiol combined with drospirenone on adrenal steroidogenesis in hyperandrogenic women with polycystic ovary syndrome. Fertil Steril 2007;88:113-17
   PubMed Web of Science ®Google Scholar
• Saeed R, Akram J, Changezi HU, Saeed M. Treatment of hirsutism in polycystic ovarian syndrome with Diane, 50 mcg ethinyl estradiol and 2 mg cyproterone acetate. Specialist 1993;9:109-12
   Google Scholar
• Venturoli S, Marescalchi O, Colombo FM, et al. A prospective randomized trial comparing low dose flutamide, finasteride, ketoconazole, and cyproterone acetate-estrogen regimens in the treatment of hirsutism. J Clin Endocrinol Metab 1999;84:1304-10
   PubMed Web of Science ®Google Scholar
• Guido M, Romualdi D, Giuliani M, et al. Drospirenone for the treatment of hirsute women with polycystic ovary syndrome: a clinical, endocrinological, metabolic pilot study. J Clin Endocrinol Metab 2004;89:2817-23
   PubMed Web of Science ®Google Scholar
• Batukan C, Muderris II. Efficacy of a new oral contraceptive containing drospirenone and ethinyl estradiol in the long-term treatment of hirsutism. Fertil Steril 2006;85:436-40
   PubMed Web of Science ®Google Scholar
• Martin KA, Chang RJ, Ehrmann DA, et al. Evaluation and treatment of hirsutism in premenopausal women: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008;93:1105-20
   PubMed Web of Science ®Google Scholar
• Lidegaard Ø, Nielsen LH, Skovlund CW, et al. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9. BMJ 2011;343:d6423
   PubMed Web of Science ®Google Scholar
• Rapkin AJ, Winer SA. Drospirenone: a novel progestin. Expert Opin Pharmacother 2007;8:989-99
   PubMed Web of Science ®Google Scholar
• Romualdi D, De Cicco S, Busacca M, et al. Clinical efficacy and metabolic impact of two different dosages of ethinyl-estradiol in association with drospirenone in normal-weight women with polycystic ovary syndrome: a randomized study. J Endocrinol Invest 2013;36:636-41
   PubMed Web of Science ®Google Scholar
• Kriplani A, Periyasamy AJ, Agarwal N, et al. Effect of oral contraceptive containing ethinyl estradiol combined with drospirenone vs. desogestrel on clinical and biochemical parameters in patients with polycystic ovary syndrome. Contraception 2010;82:139-46
   PubMed Web of Science ®Google Scholar
• Lello S, Primavera G, Colonna L, et al. Effects of two estroprogestins containing ethynilestradiol 30 microg and drospirenone 3 mg and ethynilestradiol 30 microg and chlormadinone 2 mg on skin and hormonal hyperandrogenic manifestations. Gynecol Endocrinol 2008;24:718-23
   PubMed Web of Science ®Google Scholar
• Colonna L, Pacifico V, Lello S, et al. Skin improvement with two different oestroprogestins in patients affected by acne and polycystic ovary syndrome: clinical and instrumental evaluation. J Eur Acad Dermatol Venereol 2012;26:1364-71
   PubMed Web of Science ®Google Scholar
• Raudrant D, Rabe T. Progestogens with antiandrogenic properties. Drugs 2003;63:463-92
   PubMed Web of Science ®Google Scholar
• Guido M, Romualdi D, Campagna G, et al. Ethinylestradiol-chlormadinone acetate combination for the treatment of hirsutism and hormonal alterations of normal-weight women with polycystic ovary syndrome: evaluation of the metabolic impact. Reprod Sci 2010;17:767-75
   PubMedGoogle Scholar
• Gómez Vázquez M, Navarra Amayuelas R, Lamarca M, et al. Ethinylestradiol/Chlormadinone acetate for use in dermatological disorders. Am J Clin Dermatol 2011;12:13-19
   PubMedGoogle Scholar
• Uras R, Orrù M, Pani F, et al. Endocrinological, metabolic and clinical features of treatment with oral contraceptive formulation containing ethinylestradiol plus chlormadinone acetate in nonobese women with polycystic ovary syndrome. Contraception 2010;82:131-8
   PubMed Web of Science ®Google Scholar
• Van der Spuy ZM, le Roux PA. Cyproterone acetate for hirsutism. Cochrane Database Syst Rev 2003;4:CD001125
   Google Scholar
• Mastorakos G, Koliopoulos C, Creatsas G. Androgen and lipid profiles in adolescents with polycystic ovary syndrome who were treated with two forms of combined oral contraceptives. Fertil Steril 2002;77:919-27
   PubMed Web of Science ®Google Scholar
• Batukan C, Muderris II, Ozcelik B, Ozturk A. Comparison of two oral contraceptives containing either drospirenone or cyproterone acetate in the treatment of hirsutism. Gynecol Endocrinol 2007;23:38-44
   PubMed Web of Science ®Google Scholar
• Bhattacharya SM, Jha A. Comparative study of the therapeutic effects of oral contraceptive pills containing desogestrel, cyproterone acetate, and drospirenone in patients with polycystic ovary syndrome. Fertil Steril 2012;98:1053-9
   PubMed Web of Science ®Google Scholar
• Kahraman K, Sükür YE, Atabekoğlu CS, et al. Comparison of two oral contraceptive forms containing cyproterone acetate and drospirenone in the treatment of patients with polycystic ovary syndrome: a randomized clinical trial. Arch Gynecol Obstet 2014;290:321-8
   PubMed Web of Science ®Google Scholar
• Rafie S, Borgelt L, Koepf ER, et al. Novel oral contraceptive for heavy menstrual bleeding: estradiol valerate and dienogest. Int J Womens Health 2013;5:313-21
   PubMedGoogle Scholar
• Di Carlo C, Gargano V, Sparice S, et al. Effects of an oral contraceptive containing estradiol valerate and dienogest on circulating androgen levels and acne in young patients with PCOS: an observational preliminary study. Gynecol Endocrinol 2013;29:1048-50
   PubMed Web of Science ®Google Scholar
• Nappi RE, Serrani M, Jensen JT. Noncontraceptive benefits of the estradiol valerate/dienogest combined oral contraceptive: a review of the literature. Int J Womens Health 2014;6:711-18
   PubMedGoogle Scholar
• Wild RA, Carmina E, Diamanti-Kandarakis E, et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J Clin Endocrinol Metab 2010;95:2038-49
   PubMed Web of Science ®Google Scholar
• Mancini F, Cianciosi A, Persico N, et al. Drospirenone and cardiovascular risk in lean and obese polycystic ovary syndrome patients: a pilot study. Am J Obstet Gynecol 2010;202:169.e1-8
   Google Scholar
• Carmina E. Oral contraceptives and cardiovascular risk in women with polycystic ovary syndrome. J Endocrinol Invest 2013;36:358-63
   PubMedGoogle Scholar
• Vieira CS, Martins WP, Fernandes JB, et al. The effects of 2 mg chlormadinone acetate/30 mcg ethinylestradiol, alone or combined with spironolactone, on cardiovascular risk markers in women with polycystic ovary syndrome. Contraception 2012;86:268-75
   PubMed Web of Science ®Google Scholar
• Cinar N, Harmanci A, Bayraktar M, Yildiz BO. Ethinyl estradiol-drospirenone vs ethinyl estradiol-drospirenone plus metformin in the treatment of lean women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 2013;78:379-84
   PubMed Web of Science ®Google Scholar
• van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP, et al. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ 2009;339:b2921
   PubMed Web of Science ®Google Scholar
• Luque-Ramirez M, Mendieta-Azcona C, del Rey Sanchez JM, et al. Effects of an antiandrogenic oral contraceptive pill compared with metformin on blood coagulation tests and endothelial function in women with the polycystic ovary syndrome: influence of obesity and smoking. Eur J Endocrinol 2009;160:469-80
   PubMed Web of Science ®Google Scholar
• Jick SS, Hernandez RK. Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data. BMJ 2011;342:d2151
   PubMed Web of Science ®Google Scholar
• Lopez LM, Grimes DA, Schulz KF. Steroidal contraceptives: effect on carbohydrate metabolism in women without diabetes mellitus. Cochrane Database Syst Rev 2009;4:CD006133
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Preconception care of women with diabetes. Diabetes Care 2003;26:S91-3
   Google Scholar
• Centers for Disease Control and Prevention. US medical eligibility criteria for contraceptive use. MMWR Recomm Rep 2010;59:1-86
   Google Scholar
• Morin-Papunen LC, Vauhkonen I, Koivunen RM, et al. Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study. J Clin Endocrinol Metab 2000;85:3161-8
   PubMed Web of Science ®Google Scholar
• Morin-Papunen L, Vauhkonen I, Koivunen R, et al. Metformin versus ethinyl estradiol–cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study. J Clin Endocrinol Metab 2003;88:148-56
   PubMed Web of Science ®Google Scholar
• Wu J, Zhu Y, Jiang Y, Cao Y. Effects of metformin and ethinyl estradiol–cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome. Gynecol Endocrinol 2008;24:392-8
   PubMed Web of Science ®Google Scholar
• Cibula D, Hill M, Fanta M, et al. Does obesity diminish the positive effect of oral contraceptive treatment on hyperandrogenism in women with polycystic ovarian syndrome? Hum Reprod 2001;16:940-4
   PubMedGoogle Scholar
• Elkind-Hirsch K. Low Dose OC Therapy in Women With Polycystic Ovary Syndrome (PCOS): Impact of BMI on Hyperandrogenism (BEYAZ-PCOS). ClinicalTrials.gov Identifier: NCT01360996 2011
   Google Scholar
• Sirmans SM, Pate KA. Epidemiology, diagnosis, and management of polycystic ovary syndrome. Clin Epidemiol 2013;6:1-13
   PubMed Web of Science ®Google Scholar
• Luthy IA, Begin DJ, Labrie F. Androgenic activity of synthetic progestins and spironolactone in androgen-sensitive mouse mammary carcinoma (Shionogi) cells in culture. J Steroid Biochem 1988;31:845-52
   PubMedGoogle Scholar
• Térouanne B, Tahiri B, Georget V, et al. A stable prostatic bioluminescent cell line to investigate androgen and antiandrogen effects. Mol Cell Endocrinol 2000;160:39-49
   PubMed Web of Science ®Google Scholar
• Rose LI, Underwood RH, Newmark SR, et al. Pathophysiology of spironolactone-induced gynecomastia. Ann Intern Med 1977;87:398-403
   PubMed Web of Science ®Google Scholar
• Seldin DW, Giebisch GH. Diuretic agents: clinical physiology and pharmacology. Academic Press 1997;630
   Google Scholar
• Corvol P, Michaud A, Menard J, et al. Antiandrogenic effect of spirolactones: mechanism of action. Endocrinology 1975;97:52-8
   PubMed Web of Science ®Google Scholar
• Serafini PC, Catalino J, Lobo RA. The effect of spironolactone on genital skin 5 alpha-reductase activity. J Steroid Biochem 1985;23:191-4
   PubMedGoogle Scholar
• Miles RA, Cassidenti DL, Carmina E, et al. Cutaneous application of an androstenedione gel as an in vivo test of 5 alpha-reductase activity in women. Fertil Steril 1992;58:708-12
   PubMedGoogle Scholar
• Wong IL, Morris RS, Chang L, et al. A prospective randomized trial comparing finasteride to spironolactone in the treatment of hirsute women. J Clin Endocrinol Metab 1995;80:233-8
   PubMed Web of Science ®Google Scholar
• Flores E, Bratoeff E, Cabeza M, et al. Steroid 5alpha-reductase inhibitors. Mini Rev Med Chem 2003;3:225-37
   PubMed Web of Science ®Google Scholar
• Bayram F, Muderris II, Guven M, Kelestimur F. Comparison of high dose finasteride (5 mg/day) versus low-dose finasteride (2.5 mg/day) in the treatment of hirsutism. Eur J Endocrinol 2002;147:467-71
   PubMed Web of Science ®Google Scholar
• Simard J, Luthy I, Guay J, et al. Characteristics of interaction of the antiandrogen flutamide with the androgen receptor in various target tissues. Mol Cell Endocrinol 1986;44:261-70
   PubMed Web of Science ®Google Scholar
• Domecq JP, Prutsky G, Mullan RJ, et al. Adverse effects of the common treatments for polycystic ovary syndrome: a systematic review and meta-analysis. J Clin Endocrinol Metab 2013;98:4646-54
   PubMed Web of Science ®Google Scholar
• Moghetti P, Tosi F, Tosti A, et al. Comparison of spironolactone, flutamide, and finasteride efficacy in the treatment of hirsutism: a randomized, double blind, placebo-controlled trial. J Clin Endocrinol Metab 2000;85:89-94
   PubMed Web of Science ®Google Scholar
• Wong IL, Morris RS, Chang L, et al. A prospective randomized trial comparing finasteride to spironolactone in the treatment of hirsute women. J Clin Endocrinol Metab 1995;80:233-8
   PubMed Web of Science ®Google Scholar
• Grigoriou O, Papadias C, Konidaris S, et al. Comparison of flutamide and cyproterone acetate in the treatment of hirsutism: a randomized controlled trial. Gynecol Endocrinol 1996;10:119-23
   PubMed Web of Science ®Google Scholar
• Fruzzetti F, Bersi C, Parrini D, et al. Treatment of hirsutism: comparisons between different antiandrogens with central and peripheral effects. Fertil Steril 1999;71:445-51
   PubMed Web of Science ®Google Scholar
• Beigi A, Sobhi A, Zarrinkoub F. Finasteride versus cyproterone acetate-estrogen regimens in the treatment of hirsutism. Int J Gynaecol Obstet 2004;87:29-33
   PubMed Web of Science ®Google Scholar
• Nikolaoua D, Gilling-Smith C. Hirsutism. Curr Obstet Gynaecol 2005;15:174-82
   Google Scholar
• Cusan L, Dupont A, Gomez JL, et al. Comparison of flutamide and spironolactone in the treatment of hirsutism: a randomized controlled trial. Fertil Steril 1994;61:281-7
   PubMed Web of Science ®Google Scholar
• Inal MM, Yildirim Y, Taner CE. Comparison of the clinical efficacy of flutamide and spironolactone plus Diane 35 in the treatment of idiopathic hirsutism: a randomized controlled study. Fertil Steril 2005;84:1693-7
   PubMed Web of Science ®Google Scholar
• Falsetti L, Gambera A, Legrenzi L, et al. Comparison of finasteride versus flutamide in the treatment of hirsutism. Eur J Endocrinol 1999;141:361-7
   PubMed Web of Science ®Google Scholar
• Muderris II, Bayram F, Guven M. A prospective, randomized trial comparing flutamide (250 mg/d) and finasteride (5 mg/d) in the treatment of hirsutism. Fertil Steril 2000;73:984-7
   PubMed Web of Science ®Google Scholar
• Pazos F, Escobar-Morreale HF, Balsa J, et al. Prospective randomized study comparing the long-acting gonadotropin-releasing hormone agonist triptorelin, flutamide, and cyproterone acetate, used in combination with an oral contraceptive, in the treatment of hirsutism. Fertil Steril 1999;71:122-8
   PubMed Web of Science ®Google Scholar
• Kelestimur F, Everest H, Unluhizarci K, et al. A comparison between spironolactone and spironolactone plus finasteride in the treatment of hirsutism. Eur J Endocrinol 2004;150:351-4
   PubMed Web of Science ®Google Scholar
• Tartagni MV, Alrasheed H, Damiani GR, et al. Intermittent low-dose finasteride administration is effective for treatment of hirsutism in adolescent girls: a pilot study. J Pediatr Adolesc Gynecol 2014;27:161-5
   PubMedGoogle Scholar
• Azziz R, Ehrmann D, Legro RS, et al. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. J Clin Endocrinol Metab 2001;86:1626-32
   PubMed Web of Science ®Google Scholar
• Aroda VR, Ciaraldi TP, Burke P, et al. Metabolic and hormonal changes induced by pioglitazone in polycystic ovary syndrome: a randomized, placebo-controlled clinical trial. J Clin Endocrinol Metab 2009;94:469-76
   PubMed Web of Science ®Google Scholar
• Stabile G, Borrielli I, Artenisio AC, et al. Effects of the insulin sensitizer pioglitazone on menstrual irregularity, insulin resistance and hyperandrogenism in young women with polycystic ovary syndrome. J Pediatr Adolesc Gynecol 2014;27:177-82
   PubMed Web of Science ®Google Scholar
• Du Q, Wang YJ, Yang S, et al. A systematic review and meta-analysis of randomized controlled trials comparing pioglitazone versus metformin in the treatment of polycystic ovary syndrome. Curr Med Res Opin 2012;28:723-30
   PubMed Web of Science ®Google Scholar
• Bourg CA, Phillips BB. Rosiglitazone, myocardial ischemic risk, and recent regulatory actions. Ann Pharmacother 2012;46:282-9
   PubMed Web of Science ®Google Scholar
• Tseng CH. A review on thiazolidinediones and bladder cancer in human studies. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 2014;32:1-45
   PubMed Web of Science ®Google Scholar
• Palomba S, Falbo A, Zullo F, Orio FJr. Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review. Endocr Rev 2009;30:1-50
   PubMed Web of Science ®Google Scholar
• Moghetti P, Castello R, Negri C, et al. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab 2000;85:139-46
   PubMed Web of Science ®Google Scholar
• Pasquali R, Gambineri A, Biscotti D, et al. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. J Clin Endocrinol Metab 2000;85:2767-74
   PubMed Web of Science ®Google Scholar
• Gambineri A, Pelusi C, Genghini S, et al. Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 2004;60:241-9
   PubMed Web of Science ®Google Scholar
• Maciel GA, Soares Júnior JM, Alves da Motta EL, et al. Nonobese women with polycystic ovary syndrome respond better than obese women to treatment with metformin. Fertil Steril 2004;81:355-60
   PubMed Web of Science ®Google Scholar
• Hoeger KM, Kochman L, Wixom N, et al. A randomized, 48-week, placebo-controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study. Fertil Steril 2004;82:421-9
   PubMed Web of Science ®Google Scholar
• Gambineri A, Patton L, Vaccina A, et al. Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study. J Clin Endocrinol Metab 2006;91:3970-80
   PubMed Web of Science ®Google Scholar
• Romualdi D, Giuliani M, Cristello F, et al. Metformin effects on ovarian ultrasound appearance and steroidogenic function in normal-weight normoinsulinemic women with polycystic ovary syndrome: a randomized double-blind placebo-controlled clinical trial. Fertil Steril 2010;93:2303-10
   PubMed Web of Science ®Google Scholar
• Kolodziejczyk B, Duleba AJ, Spaczynski RZ, Pawelczyk L. Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome. Fertil Steril 2000;73:1149-54
   PubMed Web of Science ®Google Scholar
• Harborne LR, Sattar N, Norman JE, Fleming R. Metformin and weight loss in obese women with polycystic ovary syndrome: comparison of doses. J Clin Endocrinol Metab 2005;90:4593-8
   PubMed Web of Science ®Google Scholar
• Baillargeon JP, Jakubowicz DJ, Iuorno MJ, et al. Effects of metformin and rosiglitazone, alone and in combination, in non obese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertil Steril 2004;82:893-902
   PubMed Web of Science ®Google Scholar
• Trolle B, Flyvbjerg A, Kesmodel U, Lauszus FF. Efficacy of metformin in obese and non-obese women with polycystic ovary syndrome: a randomized, double-blinded, placebo-controlled crossover trial. Hum Reprod 2007;22:2967-73
   PubMed Web of Science ®Google Scholar
• Cosma M, Swiglo BA, Flynn DN, et al. Clinical review: insulin sensitizers for the treatment of hirsutism: a systematic review and metaanalyses of randomized controlled trials. J Clin Endocrinol Metab 2008;93:1135-42
   PubMed Web of Science ®Google Scholar
• Unfer V, Carlomagno G, Dante G, Facchinetti F. Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials. Gynecol Endocrinol 2012;28:509-15
   PubMed Web of Science ®Google Scholar
• Guido M. Myo-inositol Versus Metformin in Obese Women With Polycystic Ovary Syndrome. ClinicalTrials.gov Identifier: NCT01791647 2012
   Google Scholar
• Creatsas G, Hassan E, Deligeoroglou E, et al. Treatment of polycystic ovarian disease during adolescence with ethinylestradiol/cyproterone acetate versus a D-Tr-6-LHRH analog. Int J Gynecol Obstet 1993;42:147-53
   PubMed Web of Science ®Google Scholar
• Carr BR, Breslau NA, Givens C, et al. Oral contraceptive pills, gonadotropin-releasing hormone agonists, or use in combination for treatment of hirsutism: a clinical research center study. J Clin Endocrinol Metab 1995;80:1169-78
   PubMedGoogle Scholar
• Carmina E, Lobo RA. Gonadotropin-releasing hormone agonist therapy for hirsutism is as effective as high dose cyproterone acetate but results in a longer remission. Hum Reprod 1997;12:663-6
   PubMed Web of Science ®Google Scholar
• Horrocks PM, London DR. Effects of long term dexamethasone treatment in adult patients with congenital adrenal hyperplasia. Clin Endocrinol (Oxf) 1987;27:635-42
   PubMedGoogle Scholar
• Steinberger E, Rodriguez-Rigau LJ, Petak SM, et al. Glucocorticoid therapy in hyperandrogenism. Baillieres Clin Obstet Gynaecol 1990;4:457-71
   PubMedGoogle Scholar
• Kaya C, Pabuccu R, Cengiz SD, Dünder I. Comparison of the effects of atorvastatin and simvastatin in women with polycystic ovary syndrome: A prospective, randomized study. Exp Clin Endocrinol Diabetes 2010;118:161-6
   PubMed Web of Science ®Google Scholar
• Panidis D, Tziomalos K, Papadakis E, et al. The role of orlistat combined with lifestyle changes in the management of overweight and obese patients with polycystic ovary syndrome. Clin Endocrinol (Oxf) 2014;80:432-8
   PubMed Web of Science ®Google Scholar
• Gao L, Zhao FL, Li SC. Statin is a reasonable treatment option for patients with Polycystic Ovary Syndrome: a meta-analysis of randomized controlled trials. Exp Clin Endocrinol Diabetes 2012;120:367-75
   PubMed Web of Science ®Google Scholar
• Kelekci KH, Kelekci S, Yengel I, et al. Cyproterone acetate or drospirenone containing combined oral contraceptives plus spironolactone or cyproterone acetate for hirsutism: randomized comparison of three regimens. J Dermatolog Treat 2012;23:177-83
   PubMed Web of Science ®Google Scholar
• Belisle S, Love EJ. Clinical efficacy and safety of cyproterone acetate in severe hirsutism: results of a multicentered Canadian study. Fertil Steril 1986;46:1015-20
   PubMed Web of Science ®Google Scholar
• Sahin Y, Bayram F, Keleştimur F, Müderris I. Comparison of cyproterone acetate plus ethinyl estradiol and finasteride in the treatment of hirsutism. J Endocrinol Invest 1998;21:348-52
   PubMed Web of Science ®Google Scholar
• Calaf J, López E, Millet A, et al. Long-term efficacy and tolerability of flutamide combined with oral contraception in moderate to severe hirsutism: a 12-month, double-blind, parallel clinical trial. J Clin Endocrinol Metab 2007;92:3446-52
   PubMed Web of Science ®Google Scholar
• Hagag P, Steinschneider M, Weiss M. Role of the combination spironolactone-norgestimate-estrogen in Hirsute women with polycystic ovary syndrome. J Reprod Med 2014;59:455-63
   PubMedGoogle Scholar
• Leelaphiwat S, Jongwutiwes T, Lertvikool S, et al. Comparison of desogestrel/ethinyl estradiol plus spironolactone versus cyproterone acetate/ethinyl estradiol in the treatment of polycystic ovary syndrome: a randomized controlled trial. J Obstet Gynaecol Res 2015;41(3):402-10
   PubMedGoogle Scholar
• Fruzzetti F, Perini D, Lazzarini V, et al. Comparison of effects of 3 mg drospirenone plus 20 mg ethinylestradiol alone or combined with metformin or cyproterone acetate on classic cardiovascular risk factors in nonobese women with polycystic ovary syndrome. Fertil Steril 2010;94:1793-8
   PubMed Web of Science ®Google Scholar
• Sahin I, Serter R, Karakurt F, et al. Metformin versus flutamide in the treatment of metabolic consequences of non-obese young women with polycystic ovary syndrome: a randomized prospective study. Gynecol Endocrinol 2004;19:115-24
   PubMed Web of Science ®Google Scholar
• Ibànez L, de Zegher F. Low-dose flutamide-metformin therapy for hyperinsulinemic hyperandrogenism in non-obese adolescents and women. Hum Reprod Update 2006;12:243-52
   PubMed Web of Science ®Google Scholar
• Ibánez L, López-Bermejo A, Díaz M, et al. Low-dose pioglitazone and low-dose flutamide added to metformin and oestro-progestagens for hyperinsulinaemic women with androgen excess: add-on benefits disclosed by a randomized double-placebo study over 24 months. Clin Endocrinol (Oxf) 2009;71:351-7
   PubMedGoogle Scholar
• Ganie MA, Khurana ML, Nisar S, et al. Improved efficacy of low-dose spironolactone and metformin combination than either drug alone in the management of women with polycystic ovary syndrome (PCOS): a six-month, open-label randomized study. J Clin Endocrinol Metab 2013;98:3599-607
   PubMed Web of Science ®Google Scholar
• Mazza A, Fruci B, Guzzi P, et al. In PCOS patients the addition of low-dose spironolactone induces a more marked reduction of clinical and biochemical hyperandrogenism than metformin alone. Nutr Metab Cardiovasc Dis 2014;24:132-9
   PubMed Web of Science ®Google Scholar
• Kazerooni T, Shojaei-Baghini A, Dehbashi S, et al. Effects of metformin plus simvastatin on polycystic ovary syndrome: a prospective, randomized, double-blind, placebo-controlled study. Fertil Steril 2010;94:2208-13
   PubMed Web of Science ®Google Scholar
• Hickey M, Higham JM, Fraser I. Progestogens with or without oestrogen for irregular uterine bleeding associated with anovulation. Cochrane Database Syst Rev 2012;9:CD001895
   Google Scholar
• Diamanti-Kandarakis E, Baillargeon JP, Iuorno MJ, et al. A modern medical quandary: polycystic ovary syndrome, insulin resistance, and oral contraceptive pills. J Clin Endocrinol Metab 2003;88:1927-32
   PubMed Web of Science ®Google Scholar
• Tang T, Lord JM, Norman RJ, et al. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev 2012;5:CD003053
   PubMed Web of Science ®Google Scholar
• Ortega-González C, Luna S, Hernández L, et al. Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005;90:1360-5
   PubMed Web of Science ®Google Scholar
• Nestler JE, Jakubowicz DJ, Evans WS, Pasquali R. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med 1998;338:1876-80
   PubMed Web of Science ®Google Scholar
• Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Consensus on infertility treatment related to polycystic ovary syndrome. Hum Reprod 2008;23:462-77
   PubMed Web of Science ®Google Scholar
• Costello M, Shrestha B, Eden J, et al. Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome. Cochrane Database Syst Rev 2007;CD005552
   PubMed Web of Science ®Google Scholar
• Lord JM, Flight IH, Norman RJ. Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome. Cochrane Database Syst Rev 2003;3:CD003053
   Google Scholar
• Kashyap S, Wells GA, Rosenwaks Z. Insulin-sensitizing agents as primary therapy for patients with polycystic ovarian syndrome. Hum Reprod 2004;19:2474-83
   PubMed Web of Science ®Google Scholar
• Pizzo A, Laganà AS, Barbaro L. Comparison between effects of myo-inositol and D-chiro-inositol on ovarian function and metabolic factors in women with PCOS. Gynecol Endocrinol 2014;30:205-8
   PubMed Web of Science ®Google Scholar
• Gerli S, Papaleo E, Ferrari A, Di Renzo GC. Randomized, double blind placebo-controlled trial: effects of myo-inositol on ovarian function and metabolic factors in women with PCOS. Eur Rev Med Pharmacol Sci 2007;11:347-54
   PubMed Web of Science ®Google Scholar
• Raffone E, Rizzo P, Benedetto V. Insulin sensitiser agents alone and in co-treatment with r-FSH for ovulation induction in PCOS women. Gynecol Endocrinol 2010;26:275-80
   PubMed Web of Science ®Google Scholar
• La Marca A, Grisendi V, Dondi G, et al. The menstrual cycle regularization following d-chiro-inositol treatment in PCOS women: a retrospective study. Gynecol Endocrinol 2014;1-5
   Google Scholar
• Oner G, Muderris II. Clinical, endocrine and metabolic effects of metformin vs N-acetyl-cysteine in women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 2011;159:127-31
   PubMed Web of Science ®Google Scholar
• Sacchinelli A, Venturella R, Lico D, et al. The Efficacy of Inositol and N-Acetyl Cysteine Administration (Ovaric HP) in Improving the Ovarian Function in Infertile Women with PCOS with or without Insulin Resistance. Obstet Gynecol Int 2014;2014:141020
   PubMedGoogle Scholar
• ESHRE Capri Workshop Group. Anovulatory infertility. Hum Reprod 1995;10:1549-53
   PubMed Web of Science ®Google Scholar
• Balen AH, Conway GS, Kaltsas G, et al. Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients. Hum Reprod 1995;10:2107-11
   PubMed Web of Science ®Google Scholar
• Bhattacharya S, Porter M, Amalraj E, et al. The epidemiology of infertility in the North East of Scotland. Hum Reprod 2009;24:3096-107
   PubMed Web of Science ®Google Scholar
• National Institute for Clinical Excellence Clinical Guideline. NICE clinical guideline 156. Fertility: assessment and treatment for people with fertility problems. 2013
   Google Scholar
• Setji TL, Brown AJ. Polycystic ovary syndrome: update on diagnosis and treatment. Am J Med 2014;127:912-19
   PubMed Web of Science ®Google Scholar
• Abu Hashim H, Ombar O, Abd Elaal I. Intrauterine insemination versus timed intercourse with clomiphene citrate in polycystic ovary syndrome: a randomized controlled trial. Acta Obstet Gynecol Scand 2011;90:344-50
   PubMedGoogle Scholar
• Morin-Papunen L, Rantala AS, Unkila-Kallio L, et al. Metformin improves pregnancy and live-birth rates in women with polycystic ovary syndrome (PCOS): a multicenter, double-blind, placebo-controlled randomized trial. J Clin Endocrinol Metab 2012;97:1492-500
   PubMed Web of Science ®Google Scholar
• Kjotrod SB, Carlsen SM, Rasmussen PE, et al. Use of metformin before and during assisted reproductive technology in non-obese young infertile women with polycystic ovary syndrome: a prospective, randomized, double-blind, multi-centre study. Hum Reprod 2011;26:2045-53
   PubMed Web of Science ®Google Scholar
• Palomba S. Metformin in Infertile PCOS Patients. ClinicalTrials.gov Identifier: NCT00501904 2007
   Google Scholar
• Legro RS, Barnhart HX, Schlaff WD, et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. Cooperative Multicenter Reproductive Medicine Network. N Engl J Med 2007;356:551-66
   PubMed Web of Science ®Google Scholar
• Siebert TI, Viola MI, Steyn DW, Kruger TF. Is metformin indicated as primary ovulation induction agent in women with PCOS? A systematic review and meta-analysis. Gynecol Obstet Invest 2012;73:304-13
   PubMed Web of Science ®Google Scholar
• Johnson MP. Metformin is reasonable option for non-obese women with infertility related to anovulatory polycystic ovary syndrome--a meta-analysis of randomised trials. Aust N Z J Obstet Gynaecol 2011;51:125-9
   PubMed Web of Science ®Google Scholar
• Misso ML, Costello MF, Garrubba M, et al. Metformin versus clomiphene citrate for infertility in non-obese women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update 2013;19:2-11
   PubMed Web of Science ®Google Scholar
• Moll E, Korevaar JC, Bossuyt PMM, van der Veen F. Does adding metformin to clomifene citrate lead to higher pregnancy rates in a subset of women with polycystic ovary syndrome? Hum Reprod 2008;23:1830-4
   PubMedGoogle Scholar
• Creanga AA, Bradley HM, McCormick C, Witkop CT. Use of metformin in polycystic ovary syndrome: a meta-analysis. Obstet Gynecol 2008;111:959-68
   PubMed Web of Science ®Google Scholar
• Badawy A, State O, Abdelgawad S. N-Acetyl cysteine and clomiphene citrate for induction of ovulation in polycystic ovary syndrome: a cross-over trial. Acta Obstet Gynecol Scand 2007;86:218-22
   PubMed Web of Science ®Google Scholar
• Misso ML, Wong JL, Teede HJ, et al. Aromatase inhibitors for PCOS: a systematic review and meta-analysis. Hum Reprod Update 2012;18:301-12
   PubMed Web of Science ®Google Scholar
• Franik S, Kremer JA, Nelen WL, Farquhar C. Aromatase inhibitors for subfertile women with polycystic ovary syndrome. Cochrane Database Syst Rev 2014;2:CD010287
   PubMed Web of Science ®Google Scholar
• NIH/NICHD Effect of letrozole versus clomiphene on live birth in women with anovulatory infertility due to polycystic ovary syndrome (PCOS): a randomized double-blind multicenter trial. Fertil Steril 2013;100:S51
   Google Scholar
• Legro RS, Brzyski RG, Diamond MP, et al. Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. N Engl J Med 2014;371:119-29
   PubMed Web of Science ®Google Scholar
• Brown J, Farquhar C, Beck J, et al. Clomiphene and anti-oestrogens for ovulation induction in PCOS. Cochrane Database Syst Rev 2009;7:CD002249
   Google Scholar
• Badawy A, Gibreal A. Clomiphene citrate versus tamoxifen for ovulation induction in women with PCOS: a prospective randomized trial. Eur J Obstet Gynecol Reprod Biol 2011;159:151-4
   PubMedGoogle Scholar
• Badawy A, Allam A, Abulatta M. Extending clomiphene treatment in clomiphene-resistant women with PCOS: a randomized controlled trial. Reprod Biomed Online 2008;16:825-9
   PubMedGoogle Scholar
• Badawy A, Inany H, Mosbah A, Abulatta M. Luteal phase clomiphene citrate for ovulation induction in women with polycystic ovary syndrome: a novel protocol. Fertil Steril 2009;91:838-41
   PubMed Web of Science ®Google Scholar
• Kosar O, Ozaksit G, Taskin MI. Luteal phase clomiphene citrate for ovulation induction in women with polycystic ovary syndrome. Arch Gynecol Obstet 2014;290:771-5
   PubMed Web of Science ®Google Scholar
• Elbohoty AE. Luteal phase versus follicular phase administration of clomiphene citrate in PCOS, a randomized controlled trial. ClinicalTrials.gov Identifier: NCT02024984 2013
   Google Scholar
• Hurst BS, Hickman JM, Matthews ML, et al. Novel clomiphene “stair-step” protocol reduces time to ovulation in women with polycystic ovarian syndrome. Am J Obstet Gynecol 2009;200:510
   PubMedGoogle Scholar
• Deveci CD, Demir B, Sengul O, et al. Clomiphene citrate ’stair-step’ protocol vs. traditional protocol in patients with polycystic ovary syndrome: a randomized controlled trial. Arch Gynecol Obstet 2015;291(1):179-84
   PubMedGoogle Scholar
• Palomba S, Falbo A, Giallauria F, et al. Six weeks of structured exercise training and hypocaloric diet increases the probability of ovulation after clomiphene citrate in overweight and obese patients with polycystic ovary syndrome: a randomized controlled trial. Hum Reprod 2010;25:2783-91
   PubMed Web of Science ®Google Scholar
• Palomba S, Falbo A, Orio FJr, et al. Efficacy of laparoscopic ovarian diathermy in clomiphene citrate-resistant women with polycystic ovary syndrome: relationships with chronological and ovarian age. Gynecol Endocrinol 2006;22:329-35
   PubMed Web of Science ®Google Scholar
• El Refaeey A, Selem A, Badawy A. Combined coenzyme Q10 and clomiphene citrate for ovulation induction in clomiphene-citrate-resistant polycystic ovary syndrome. Reprod Biomed Online 2014;29:119-24
   PubMed Web of Science ®Google Scholar
• Ismail AM, Hamed AH, Saso S, Thabet HH. Adding l-carnitine to clomiphene resistant PCOS women improves the quality of ovulation and the pregnancy rate. A randomized clinical trial. Eur J Obstet Gynecol Reprod Biol 2014;180:148-52
   PubMed Web of Science ®Google Scholar
• Azargoon A, Ghorbani R, Faraji Z. Effects of simvastatin pretreatment on clomiphene response in clomiphene-resistant women with polycystic ovary syndrome. J Family Reprod Health 2013;7:165-70
   PubMedGoogle Scholar
• Sinawat S, Buppasiri P, Lumbiganon P, Pattanittum P. Long versus short course treatment with metformin and clomiphene citrate for ovulation induction in women with PCOS. Cochrane Database Syst Rev 2012;10:CD006226
   PubMedGoogle Scholar
• Begum MR, Akhter S, Ehsan M, et al. Pretreatment and co-administration of oral anti-diabetic agent with clomiphene citrate or rFSH for ovulation induction in clomiphene-citrate-resistant polycystic ovary syndrome. J Obstet Gynaecol Res 2013;39:966-73
   PubMedGoogle Scholar
• Palomba S, Falbo A, Battista L, et al. Laparoscopic ovarian diathermy versus clomiphene citrate plus metformin as second-line strategy for infertile anovulatory patients with polycystic ovary syndrome: a randomized controlled trial. Am J Obstet Gynecol 2010;202:577e1-8
   Google Scholar
• Abu Hashim H, Shokeir T, Badawy A. Letrozole versus combined metformin and clomiphene citrate for ovulation induction in clomiphene-resistant women with polycystic ovary syndrome: a randomized controlled trial. Fertil Steril 2010;94:1405-9
   PubMed Web of Science ®Google Scholar
• Ng EH, Wat NM, Ho PC. Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomiphene resistant polycystic ovaries: a randomized, double-blinded placebo-controlled trial. Hum Reprod 2001;16:1625-31
   PubMed Web of Science ®Google Scholar
• Moll E, van der Veen F, van Wely M. The role of metformin in polycystic ovary syndrome: a systematic review. Hum Reprod Update 2007;13:527-37
   PubMed Web of Science ®Google Scholar
• Cheraghi E, Soleimani Mehranjani M, Shariatzadeh MA, et al. Co-Administration of Metformin and N-Acetyl Cysteine Fails to Improve Clinical Manifestations in PCOS Individual Undergoing ICSI. Int J Fertil Steril 2014;8:119-28
   PubMedGoogle Scholar
• Badawy A, Mosbah A, Shady M. Anastrozole or letrozole for ovulation induction in clomiphene-resistant women with polycystic ovarian syndrome: a prospective randomized trial. Fertil Steril 2008;89:1209-12
   PubMedGoogle Scholar
• Mitwally MFM, Casper RF. Aromatase inhibition: a novel method of ovulation induction in women with polycystic ovarian syndrome. Reprod Technol 2000;10:244-7
   Google Scholar
• Mitwally MFM, Casper RF. Use of an AI for induction of ovulation in patients with an inadequate response to clomiphene citrate. Fertil Steril 2000;75:305-9
   Google Scholar
• Elnashar A, Fouad H, Eldosoky M, Saeid N. Letrozole induction of ovulation in women with clomiphene citrate-resistant polycystic ovary syndrome may not depend on the period of infertility, the body mass index, or the luteinizing hormone/follicle-stimulating hormone ratio. Fertil Steril 2006;85:511-13
   PubMed Web of Science ®Google Scholar
• Badawy A, Mosbah A, Tharwat A, Eid M. Extended letrozole therapy for ovulation induction in clomiphene-resistant women with polycystic ovary syndrome: a novel protocol. Fertil Steril 2009;92:236-9
   PubMed Web of Science ®Google Scholar
• Kamath MS, Aleyamma TK, Chandy A, George K. Aromatase inhibitors in women with clomiphene citrate resistance: a randomized, double-blind, placebo-controlled trial. Fertil Steril 2010;94:2857-9
   PubMedGoogle Scholar
• Abu Hashim H, Mashaly AM, Badawy A. Letrozole versus laparoscopic ovarian diathermy for ovulation induction in clomiphene-resistant women with polycystic ovary syndrome: a randomized controlled trial. Arch Gynecol Obstet 2010;282:567-71
   PubMed Web of Science ®Google Scholar
• Abd Elgafor I. Efficacy of combined metformin-letrozole in comparison with bilateral ovarian drilling in clomiphene-resistant infertile women with polycystic ovarian syndrome. Arch Gynecol Obstet 2013;288:119-23
   PubMed Web of Science ®Google Scholar
• Costello MF, Misso ML, Wong J, et al. The treatment of infertility in polycystic ovary syndrome: a brief update. Aust N Z J Obstet Gynaecol 2012;52:400-3
   PubMed Web of Science ®Google Scholar
• Nugent D, Vandekerckhove P, Hughes E, et al. Gonadotropin therapy for ovulation induction in subfertility associated with polycystic ovary syndrome. Cochrane Database Syst Rev 2000;4:CD000410
   Google Scholar
• Bayram N, van Wely M, van Der Veen F. Recombinant FSH versus urinary gonadotropins or recombinant FSH for ovulation induction in subfertility associated with polycystic ovary syndrome. Cochrane Database Syst Rev 2001;2:CD002121
   Google Scholar
• Balen A, Platteau P, Andersen AN, et al. Highly purified FSH is as efficacious as recombinant FSH for ovulation induction in women with WHO Group II anovulatory infertility: a randomized controlled non-inferiority trial. Hum Reprod 2007;22:1816-23
   PubMed Web of Science ®Google Scholar
• Homburg R, Howles CM. Low dose FSH therapy for anovulatory infertility associated with polycystic ovary syndrome: rationale, reflections and refinements. Hum Reprod Update 1999;5:493-9
   PubMed Web of Science ®Google Scholar
• Casadei L, Puca F, Emidi E, et al. Sequential low-dose step-up and step-down protocols with recombinant follicle-stimulating hormone in polycystic ovary syndrome: prospective comparison with step-down protocol. Arch Gynecol Obstet 2012;286:1291-7
   PubMedGoogle Scholar
• Homburg R, Hendriks ML, König TE, et al. Clomifene citrate or low-dose FSH for the first-line treatment of infertile women with anovulation associated with polycystic ovary syndrome: a prospective randomized multinational study. Hum Reprod 2012;27:468-73
   PubMed Web of Science ®Google Scholar
• Lin H, Li Y, Li L, et al. Is a GnRH antagonist protocol better in PCOS patients? A meta-analysis of RCTs. PLoS One 2014;9:e91796
   Google Scholar
• Westergaard LW, Bossuyt PM, Van der Veen F, van Wely M. WITHDRAWN: Human menopausal gonadotropin versus recombinant follicle stimulation hormone for ovarian stimulation in assisted reproductive cycles. Cochrane Database Syst Rev 2011;2:CD003973
   Google Scholar
• Al-Inany HG, Youssef MA, Aboulghar M, et al. Gonadotropin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev 2011;11:CD001750
   Google Scholar
• Xiao J, Chen S, Zhang C, Chang S. Effectiveness of GnRH antagonist in the treatment of patients with polycystic ovary syndrome undergoing IVF: a systematic review and meta analysis. Gynecol Endocrinol 2013;29:187-91
   PubMed Web of Science ®Google Scholar
• Youssef MA, Van der Veen F, Al-Inany HG, et al. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology. Cochrane Database Syst Rev 2014;10:CD008046
   PubMed Web of Science ®Google Scholar
• O’Neill KE, Senapati S, Dokras A. Use of gonadotropin-releasing hormone agonist trigger during in vitro fertilization is associated with similar endocrine profiles and oocyte measures in women with and without polycystic ovary syndrome. Fertil Steril 2014;pii:S0015-282 (14)02224-9
   Google Scholar
• Kol S, Homburg R, Alsbjerg B, Humaidan P. The gonadotropin-releasing hormone antagonist protocol-the protocol of choice for the polycystic ovary syndrome patient undergoing controlled ovarian stimulation. Acta Obstet Gynecol Scand 2012;91:643-7
   PubMed Web of Science ®Google Scholar
• Ghanem ME, Elboghdady LA, Hassan M, et al. Clomiphene citrate co-treatment with low dose urinary FSH versus urinary FSH for clomiphene resistant PCOS: randomized controlled trial. J Assist Reprod Genet 2013;30:1477-85
   PubMed Web of Science ®Google Scholar
• Figueiredo JB, Nastri CO, Vieira AD, Martins WP. Clomiphene combined with gonadotropins and GnRH antagonist versus conventional controlled ovarian hyperstimulation without clomiphene in women undergoing assisted reproductive techniques: systematic review and meta-analysis. Arch Gynecol Obstet 2013;287:779-90
   PubMed Web of Science ®Google Scholar
• Costello MF, Chapman M, Conway U. A systematic review and meta-analysis of randomized controlled trials on metformin co-administration during gonadotropin ovulation induction or IVF in women with polycystic ovary syndrome. Hum Reprod 2006;21:1387-99
   PubMed Web of Science ®Google Scholar
• Palomba S, Falbo A, La Sala GB. Metformin and gonadotropins for ovulation induction in patients with polycystic ovary syndrome: a systematic review with meta-analysis of randomized controlled trials. Reprod Biol Endocrinol 2014;12:3
   PubMed Web of Science ®Google Scholar
• Tso LO, Costello MF, Albuquerque LE, et al. Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome. Cochrane Database Syst Rev 2009;2:CD006105
   PubMedGoogle Scholar
• Palomba S, Falbo A, La Sala GB. Effects of metformin in women with polycystic ovary syndrome treated with gonadotropins for in vitro fertilisation and intracytoplasmic sperm injection cycles: a systematic review and meta-analysis of randomised controlled trials. BJOG 2013;120:267-76
   PubMed Web of Science ®Google Scholar
• Palomba S, Falbo A, Carrillo L, et al. Metformin reduces risk of ovarian hyperstimulation syndrome in patients with polycystic ovary syndrome during gonadotropin-stimulated in vitro fertilization cycles: a randomized, controlled trial. Fertil Steril 2011;96:1384-90. e4
   PubMed Web of Science ®Google Scholar
• Palomba S, Falbo A, Di Cello A, et al. Does metformin affect the ovarian response to gonadotropins for in vitro fertilization treatment in patients with polycystic ovary syndrome and reduced ovarian reserve? A randomized controlled trial. Fertil Steril 2011;96:1128-33
   PubMed Web of Science ®Google Scholar
• Kumbak B, Kahraman S. Efficacy of metformin supplementation during ovarian stimulation of lean PCOS patients undergoing in vitro fertilization. Acta Obstet Gynecol Scand 2009;88:563-8
   PubMed Web of Science ®Google Scholar
• Decanter C, Robin G, Thomas P, et al. First intention IVF protocol for polycystic ovaries: does oral contraceptive pill pretreatment influence COH outcome? Reprod Biol Endocrinol 2013;11:54
   PubMed Web of Science ®Google Scholar
• Haydardedeoglu B, Kilicdag EB, Parlakgumus AH, Zeyneloglu HB. IVF/ICSI outcomes of the OCP plus GnRH agonist protocol versus the OCP plus GnRH antagonist fixed protocol in women with PCOS: a randomized trial. Arch Gynecol Obstet 2012;286:763-9
   PubMed Web of Science ®Google Scholar
• Papanikolaou EG, Polyzos NP, Humaidan P, et al. Aromatase inhibitors in stimulated IVF cycles. Reprod Biol Endocrinol 2011;9:85
   PubMedGoogle Scholar
• Fauser BCJM, Tarlatzis BC, Rebar RW, et al. Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril 2012;97:28-38. e25
   PubMed Web of Science ®Google Scholar
• Anderson SA, Barry JA, Hardiman PJ. Risk of coronary heart disease and risk of stroke in women with polycystic ovary syndrome: a systematic review and meta-analysis. Int J Cardiol 2014;176:486-7
   PubMed Web of Science ®Google Scholar
• Kocer D, Bayram F, Diri H. The effects of metformin on endothelial dysfunction, lipid metabolism and oxidative stress in women with polycystic ovary syndrome. Gynecol Endocrinol 2014;30:367-71
   PubMed Web of Science ®Google Scholar
• Ilie IR, Marian I, Mocan T, et al. Ethinylestradiol30μg-drospirenone and metformin: could this combination improve endothelial dysfunction in polycystic ovary syndrome? BMC Endocr Disord 2012;12:9
   PubMedGoogle Scholar
• Kaya MG, Calapkorur B, Karaca Z, et al. The effects of treatment with drospirenone/ethinyl oestradiol alone or in combination with metformin on elastic properties of aorta in women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 2012;77:885-92
   PubMed Web of Science ®Google Scholar
• Tang T, Glanville J, Hayden CJ, et al. Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study. Hum Reprod 2006;21:80-9
   PubMed Web of Science ®Google Scholar
• Studen KB, Sebestjen M, Pfeifer M, Prezelj J. Influence of spironolactone treatment on endothelial function in non-obese women with polycystic ovary syndrome. Eur J Endocrinol 2011;164:389-95
   PubMed Web of Science ®Google Scholar
• Raval AD, Hunter T, Stuckey B, Hart RJ. Statins for women with polycystic ovary syndrome not actively trying to conceive. Cochrane Database Syst Rev 2011;10:CD008565
   Google Scholar
• Shafiee MN, Khan G, Ariffin R, et al. Preventing endometrial cancer risk in polycystic ovarian syndrome (PCOS) women: could metformin help? Gynecol Oncol 2014;132:248-53
   PubMedGoogle Scholar
• Haoula Z, Salman M, Atiomo W. Evaluating the association between endometrial cancer and polycystic ovary syndrome. Hum Reprod 2012;27:1327-31
   PubMed Web of Science ®Google Scholar
• Cheung AP. Ultrasound and menstrual history in predicting endometrial hyperplasia in polycystic ovary syndrome. Obstet Gynecol 2001;98:325-31
   PubMed Web of Science ®Google Scholar
• Reed SD, Newton KM, Garcia RL, et al. Complex hyperplasia with and without atypia: clinical outcomes and implications of progestin therapy. Obstet Gynecol 2010;116:365-73
   PubMedGoogle Scholar
• Gallos ID, Krishan P, Shehmar M, et al. Relapse of endometrial hyperplasia after conservative treatment: a cohort study with long-term follow-up. Hum Reprod 2013;28:1231-6
   PubMed Web of Science ®Google Scholar
• Hohmann H, Creinin MD. The contraceptive implant. Clin Obstet Gynecol 2007;50:907-17
   PubMed Web of Science ®Google Scholar
• Lin M, Xu X, Wang Y, et al. Evaluation of a levonorgestrel-releasing intrauterine system for treating endometrial hyperplasia in patients with polycystic ovary syndrome. Gynecol Obstet Invest 2014;78:41-4
   PubMed Web of Science ®Google Scholar
• Stanosz S, von Mach-Szczypiński J, Sieja K, Kociuszkiewicz J. Micronized estradiol and progesterone therapy in primary, preinvasive endometrial cancer (1A/G1) in young women with polycystic ovarian syndrome. J Clin Endocrinol Metab 2014;26:jc20141693
   Google Scholar
• Shao R, Li X, Feng Y, et al. Direct effects of metformin in the endometrium: a hypothetical mechanism for the treatment of women with PCOS and endometrial carcinoma. J Exp Clin Cancer Res 2014;33:41
   PubMedGoogle Scholar
• Erdemoglu E, Güney M, Giray SG, et al. Effects of metformin on mammalian target of rapamycin in a mouse model of endometrial hyperplasia. Eur J Obstet Gynecol Reprod Biol 2009;145:195-9
   PubMed Web of Science ®Google Scholar
• Wang YL, Xie Y, Yu L, et al. Metformin promotes progesterone receptor expression via inhibition of mammalian target of rapamycin (mTOR) in endometrial cancer cells. J Steroid Biochem Mol Biol 2011;126:113-20
   PubMedGoogle Scholar
• Session DR, Kalli KR, Tummon IS, et al. Treatment of atypical endometrial hyperplasia with an insulin-sensitizing agent. Gynecol Endocrinol 2003;17:405-7
   PubMed Web of Science ®Google Scholar
• Legro RS, Zaino RJ, Demers LM, et al. The effects of metformin and rosiglitazone, alone and in combination, on the ovary and endometrium in polycystic ovary syndrome. Am J Obstet Gynecol 2007;196:402
   PubMed Web of Science ®Google Scholar
• Shen ZQ, Zhu HT, Lin JF. Reverse of progestin-resistant atypical endometrial hyperplasia by metformin and oral contraceptives. Obstet Gynecol 2008;112:465-7
   PubMed Web of Science ®Google Scholar
• Venturella R, Lico D, Sarica A, et al. OvAge: a new methodology to quantify ovarian reserve combining clinical, biochemical and 3D-ultrasonographic parameters. J Ovarian Res 2015;8:21
   PubMed Web of Science ®Google Scholar
• Viollet B, Guigas B, Sanz Garcia N, et al. Cellular and molecular mechanisms of metformin: an overview. Clin Sci 2012;122:253
   PubMed Web of Science ®Google Scholar
• Attia GR, Rainey WE, Carr BR. Metformin directly inhibits androgen production in human thecal cells. Fertil Steril 2001;76:517-24
   PubMed Web of Science ®Google Scholar
• Kurzthaler D, Hadziomerovic-Pekic D, Wildt L, Seeber BE. Metformin induces a prompt decrease in LH-stimulated testosterone response in women with PCOS independent of its insulin-sensitizing effects. Reprod Biol Endocrinol 2014;12:98
   PubMed Web of Science ®Google Scholar
• Velazquez EM, Mendoza S, Hamer T, et al. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyper- androgenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 1994;43:647-54
   PubMed Web of Science ®Google Scholar